All News
GLP-1 Receptor Agonists: Impacts Beyond Metabolism?
The GLP-1 story has been hard to miss this year, and at ACR Convergence, it’s clear that these drugs are starting to make real waves in rheumatology. Across multiple abstracts, investigators have used a large real-world dataset, the TriNetX network, to explore how GLP-1 receptor agonists (GLP-1RAs) might influence cardiovascular, renal and immune-mediated outcomes in our patients.
Read Article
ACR25 - Day 1 Report
ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content.
Read Article
The Rapidly Evolving Landscape of Cellular and Immune-based Therapies
A transformation is now underway in rheumatology, where cellular and immune therapies are redefining how we treat autoimmune diseases.
Read Article
ACR25 Best Abstracts - Day 1
The RheumNow Faculty have run through day one at ACR25 and come with a few of their favorites - some what you expected but some of these are gems.
Read Article
#ACR25 Abstr#0773 Anti-MDA5 ab is assoc. with progressive DM-ILD. But MDA5 expression is also upregulated in IPF. Any new biomarker which can link these ILD?
Measuring reactivity to MDA5 (aa 201-300) epitope peptide may help identify poor ILD prognostics (with/out DM) @RheumNow https://t.co/rziwihKfIr
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What is the #frequency of #CTD #ILD in #USA?
Data from #Marketscan >9K & #Optum ~20k CTD-ILD Pts
56-65 yrs, 3/4 F
?under ascertained #RA-ILD - low % but #SSc-ILD approx 16% clinically relevant
Same as Ont, Canada #SSc-ILD %
Not rare
#ACR25 @RheumNow @ACRheum
Abst#0154 https://t.co/imfSyOtYpC
Links:
Janet Pope Janetbirdope ( View Tweet)
Increased risk of psoriatic arthritis with obesity. A preview to Abstract#2687 Scher J @RheumNow #ACR25 https://t.co/cMbrQnq8YG
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
High prevalence of sleep related symptoms in PsA pts!
-Snoring 53%
-Morning fatigue 68%
-Obstructive Sleep Apnea in 50%
14% mild 19% moderate 17% severe
Estimated prevalence 36%
No correlation between OSA and PsA disease activity or comorbidities
But small cohort! https://t.co/VKe7qcHIRm
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR25 Abstr#663 “Off-the-Shelf” iPSC-derived CAR-T is coming soon! Promising data on 8 #SLE patients in Phase 1. Advantages over autologous/allogenic:
-No apheresis
-No conditioning chemo
-Shorter hospital stays ~3 days
-Ability to redose in partial responder
@RheumNow https://t.co/pbem7A5Iq5
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Dr. Ogdie on emerging PsA tx:
“It’s not just about the pharmacotherapy but also about making the patient feel better”
Also, weight loss is incredibly important but also incredibly hard. Losing weight is more impt than the type of diet a patient should be on.
#ACR25 @RheumNow https://t.co/FN3EEowkDP
Links:
sheila RHEUMarampa ( View Tweet)
Why do we need to identify early PsA?
🔅Improve symptoms
🔅Prevent radiographic progression
🔅Preserve function
☝️Recent data show that erosions are prevalent in early PsA but lower if symptom duration is <6 mos.
#ACR25 @RheumNow https://t.co/sEGXzd8RiD
Links:
sheila RHEUMarampa ( View Tweet)
What are the RFs for progression of Pso to PsA?
🔸PsO disease severity - 3.2x risk —>PsA
🔸Phenotype - nail involvement
🔸Obesity - 6x higher risk of developing PsA
🔸MSK symptoms - arthralgia & heel pain
#ACR25 @RheumNow https://t.co/UPXuxBPyKI
Links:
sheila RHEUMarampa ( View Tweet)
The severity of skin psoriasis increases the risk of psoriatic arthritis. Scher J @RheumNow #ACR25 https://t.co/EI0ACWACHy
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease
SGLT-2 inhibitors offer benefits beyond glycemic control, such as cardioprotective and nephroprotective effects, and modest weight loss. A recent study also suggests they may have immunomodulatory effects and https://t.co/grsgHFQic5
Dr. John Cush RheumNow ( View Tweet)
Is tocilizumab equally effective in ischemic vs. non-ischemic GCA?
Ischemic = vision, jaw claudication, or CVA
Remission at 6 mo higher in non-ischemic group then with equalization at month 12
No major difference in GCs at month 12
@RheumNow #ACR25 #Abst0739 https://t.co/OeYggSQYx8
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
RA may age the immune system by nearly two decades.
IgG glycome profiles showed inflammatory aging even in early RA, tied to low fitness & high inflammation.
Improving muscle & fitness may help reverse this biologic clock.
@RheumNow #ACR25 Abstract #0835
Jiha Lee JihaRheum ( View Tweet)
We need more biomarkers in GCA - what about fibrinogen?
Miller et al retrospectively compared CRP, ESR, and fibrinogen at different points in GCA dx
Fibrinogen (and ESR/CRP) only helpful prior to initiation GC with comparable performance
@RheumNow #ACR25 Abst #0750 https://t.co/q5gFxDMnTy
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Can tissue give us an underlying diagnosis in aortitis?
Dr. Kermani breaks down the autoimmune differential based on histopathology
@RheumNow #ACR25 https://t.co/twcH021dxS
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Abstract 0842
💡 Urinary biomarkers as the next frontier for monitoring lupus nephritis activity
🔹 Proteinuria didn’t track w/ histologic activity
🔹 IL-16 & sCD163 correlated at baseline only
🔹 Urinary Tenascin C & BAFF correlated w/ activity at 1 yr
@RheumNow #ACR25
Akhil Sood MD, MS AkhilSoodMD ( View Tweet)
2 year extension data from SELECT-GCA:
Patients in remission who remained on upadacitinib 15mg daily after 1 year had 90% reduced risk of flare compared to those who switched to placebo
Higher rates zoster, CK elevation in UPA group
#ACR25 @RheumNow #ACRBest https://t.co/jf8Dh2wCBj
Brian Jaros, MD Dr_Brian_MD ( View Tweet)
